Search

Your search keyword '"Shibolet, O."' showing total 305 results

Search Constraints

Start Over You searched for: Author "Shibolet, O." Remove constraint Author: "Shibolet, O."
305 results on '"Shibolet, O."'

Search Results

1. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

2. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

3. A global research priority agenda to advance public health responses to fatty liver disease

7. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

10. Advancing the global public health agenda for NAFLD: a consensus statement

11. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

12. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

13. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

20. A Pre-Colonoscopy Personalized Digital Platform Markedly Reduces Ambulatory Colonoscopy 'No-Show' rates.

27. A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)

28. Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial

29. O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

34. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

35. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

36. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

37. HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study

38. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial

39. The Real-World Israeli Experience of Treating Chronic Hepatitis C, Genotype 1 Patients with Advanced Fibrosis with Paritaprevir/Ritonavir/Ombitasvir, Dasabuvir with or without Ribavirin: A Large Multi-Center Cohort

41. C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy

42. C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

43. Long-term culture and expansion of primary human hepatocytes

48. WS16.6 Is primary sclerosing cholangitis (PSC) a cystic fibrosis-related disorder? Electrophysiological testing and full sequencing of the CFTR gene

Catalog

Books, media, physical & digital resources